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Abstract
Background Non-adherence is a major obstacle with
long-term daily statin therapy.
Objective This retrospective study reviewed the medical
records of patients with hyperlipidemia during an 8-year
period in a private internal medicine practice. Periodic
dosing was negotiated following several patients’ refusal of
statin therapy because of muscle aches or cost.
Methods The clinical impetus was patient adherence to
statin therapy. Treatment was initiated by dispensing
rosuvastatin or atorvastatin in a stepwise patient-directed
approach (from two times/week to three times/week to
every other day, up to five times/week). The primary
endpoint was to assess the concentration of low-density
lipoprotein cholesterol (LDL-C) and the total cholesterol/
high-density lipoprotein cholesterol (TC/HDL-C) ratio
with patient-directed dosing intervals. The secondary
endpoint was a head-to-head comparison of atorvastatin
and rosuvastatin to evaluate the mean decrease in the LDL-
C and TC/HDL-C ratio.
Results Chart review identified 46 patients who had been
treated. Two patients with persistent myalgia terminated
treatment before 12 weeks. Among the remaining 44
patients, 20 received doses of rosuvastatin from 15 to
100 mg per week, and 24 received atorvastatin from 20 to
140 mg per week. There was a significant decrease from
pre-treatment in the mean TC/HDL-C ratio of 1.72
(31.1 %, P \ 0.0001) and mean LDL-C of 43.3 mg/dL
(30.2 %, P \ 0.0001). An independent samples t-test
showed a non-significant reduction of the mean TC/HDL-C
ratio and LDL-C with rosuvastatin versus atorvastatin.
Conclusion Periodic dosing of rosuvastatin or atorva-
statin using a gradual, patient-directed, stepwise
approach guided by cholesterol levels is an effective
method of lipid lowering and carried a favorable
95.6 % adherence rate.
1 Introduction
Lowering the low-density lipoprotein (LDL-C) and total
cholesterol/high-density lipoprotein cholesterol (TC/HDL-
C) [1] ratio is associated with significant reduction in
coronary atherosclerotic morbidity and mortality rates [2,
3]. Studies have found myalgia and muscle cramps repor-
ted by 10.5–60 % of patients treated with statins [4, 5]. In
clinical practice, patient concerns over cost and adverse
effects must be addressed and at times negotiated to
achieve a therapeutic goal. During any 2-year period,
between 25.4 and 40.1 % of patients may become non-
adherent to a daily statin regimen [6]. Periodic dosing of
rosuvastatin or atorvastatin has been described in previous
studies [7–9] given their long physiologic half-life and a
plasma half-life seven times greater than simvastatin. We
examine the process of periodic dosing of rosuvastatin or
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atorvastatin to reach therapeutic goals and promote patient
adherence over an 8-year period.
2 Methods
In 2002, several patients in a private internal medicine
practice, who had failed to improve their lipid profile with
non-pharmacologic options, had stopped simvastatin
treatment because of myalgias. These patients were given
the option to try periodic statin therapy to achieve a TC/
HDL-C ratio less than 5. Over the next 6 months, a
selection process was standardized and offered to other
patients who stopped taking their statin because of myal-
gias or cost. Patients who were adherent to their prescribed
statin treatment were excluded. During a 7-month review
of medication profiles, 46 patients (Table 1) were identified
who had chosen a non-daily dosing schedule during an
8-year period since 2002. Each patient was given 14 tab-
lets: 20 patients were given rosuvastatin 5 mg tablets, 24
were given 10 mg tablets of atorvastatin, and 2 patients
were unable to tolerate any dose. Instructions for the first
week were to take one tablet on Monday and a second
tablet on Wednesday. They were then to take a tablet on
Monday, Wednesday, and Friday for the next 4 weeks, and
follow-up in the office with a lipid profile. During the office
visit, post-treatment activity and lifestyle concerns were
addressed, as well as the results of the lipid profile. Fol-
lowing a discussion with the patient about the lipid profile
results and their perceptions of either the 30 mg weekly
dose of atorvastatin or 15 mg of rosuvastatin; each patient
was given the choice of maintaining the therapy, doubling
the mg dose, or increasing the frequency up to 5 days per
week. The initial post-treatment interview and lipid profile
directed that a prescription should be given for 30 addi-
tional tablets of the negotiated dose to ‘‘take as directed.’’
Subsequent lipid testing was performed at 3- to 6-month
intervals until the TC/HDL-C goal of less than 5 was
achieved. Stepwise dosing was titrated down if myalgias
arose or as per patient request. The primary endpoint in a
retrospective chart review was to assess the concentration
of LDL-C and the TC/HDL-C ratio with patient-selected
atorvastatin and rosuvastatin dosing intervals. The sec-
ondary endpoint was a head-to-head comparison of the
lipid reductions with atorvastatin versus rosuvastatin. Sta-
tistical analyses to compare pre-treatment and post-treat-
ment LDL-C level and TC/HDL-C ratio in the whole group
were performed using a paired-samples t-test. An inde-
pendent samples t-test was conducted to compare pre- and
post-treatment LDL-C level and TC/HDL-C ratio reduction
in the rosuvastatin verses atorvastatin groups. Results were
expressed as means and 95 % confidence intervals (CIs). A
P value of less than 0.05 was considered statistically sig-
nificant. All data were processed and analyzed using SPSS,
version 21 (IBM Inc., Armonk, NY, USA). An institutional
review board approved the ethics of this study.
3 Results
The patients ranged from 46 to 79 years of age and were
treated for a mean duration of 37 months (range 2–99) with
titration of atorvastatin from 10 to 40 mg and rosuvastatin
from 5 to 20 mg. Two patients (4.3 %) failed to tolerate
any dose of statin, and three patients (6.5 %) decided to
take their medication no more than twice weekly (which
was not related to myalgias). Of the 44 patients treated
with either rosuvastatin or atorvastatin, there was a statis-
tically significant decrease from baseline in the mean LDL-
C level of 43.3 mg/dL (30.2 %) (95 % CI 34–52.6,
P \ 0.0001) (Fig. 1, left). In the atorvastatin group, the
target TC/HDL-C ratio was achieved in two patients
(8.3 %) with 2-days/week therapy, in eight patients
(33.3 %) with 3-days/week therapy, in ten patients
(41.7 %) with therapy every other day, and in four patients
(16.7 %) with 5-days/week therapy. In the rosuvastatin
group, the target TC/HDL-C ratio was achieved in one
patient (5 %) with 2-days/week therapy, in eight patients
(40 %) with 3-days/week therapy, in seven patients (35 %)
with therapy every other day, and in four patients (20 %)
with 5-days/week therapy. There was also a statistically
significant decrease from pre-treatment levels in the mean
TC/HDL-C ratio of 1.72 (31.1 %) (95 % CI 1.4–2,
P \ 0.0001) (Fig. 1, right). In terms of total weekly dose
of these two statins, 50 % of the patients were controlled
with 17.5–30 mg per week of rosuvastatin or with
20–50 mg per week of atorvastatin (Fig. 2). The maximum
weekly dose of 100 mg or more was needed in 5 % of the
rosuvastatin group and in 12.5 % of the atorvastatin group.







Age, years 69 (10.6) 71 (10.3) 66 (10.6)
Female (%) 31.8 50.0 50.0
Male (%) 68.2 56.7 43.3
Pre-treatment LDL 143 (38.5) 138 (43) 149 (32)
Pre-treatment CH/HDL 5.4 (1.3) 5.2 (1.3) 5.6 (1.3)
Doses per month 14.9 (3.5) 14.7 (3.6) 15.1 (3.6)
Months of treatment 36.9 36.5 37.3
Data are presented as mean (SD) unless otherwise indicated
CH cholesterol, HDL high-density lipoprotein, LDL low-density
lipoprotein, SD standard deviation
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The head-to-head comparison failed to show a statistically
significant difference between rosuvastatin and atorvastatin
in the reduction in mean LDL-C concentration. Rosuvast-
atin produced a 33.9 % reduction compared with a 26.8 %
reduction with atorvastatin, with a mean difference in
absolute LDL-C reduction of 13.62 mg/dL between groups
(95 % CI -4.8–32, P = 0.143) (Fig. 3, left). Reduction of
the mean TC/HDL-C ratio with rosuvastatin was 32.9 %
compared with a 30.8 % reduction with atorvastatin. The
mean difference in TC/HDL-C ratio reduction of 0.27
between both groups was not statistically significant 95 %
CI -0.9–0.4, P = 0.399) (Fig. 3, right).
Fig. 3 Head-to-head comparison of LDL-C level (left) and TC/HDL ratio (right) reduction in the atorvastatin and rosuvastatin group. HDL high-
density lipoprotein, LDL-C low-density lipoprotein cholesterol, TC total cholesterol
Fig. 1 Comparison of pre- and post-treatment LDL-C level (left) and TC /HDL ratio (right) in the 44 patients. HDL high-density lipoprotein,
LDL-C low-density lipoprotein cholesterol, TC total cholesterol
Fig. 2 Weekly cumulative dose of rosuvastatin or atorvastatin
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4 Discussion
The clinical impact of long-term statin use may be com-
promised by patient concerns, including myalgias and cost,
resulting in decreased adherence. This study demonstrates
that periodic dosing of rosuvastatin or atorvastatin is
effective in achieving a desirable LDL-C and TC/HDL-C
ratio for up to 8 years. Rosuvastatin and atorvastatin were
selected because of their uniquely long in vivo activity.
The half-life of atorvastatin is approximately 14 h, and the
half-life of its HMG-CoA reductase inhibiting metabolites
approaches 20–30 h. Rosuvastatin has an extended half-life
of 19 h as well as enterohepatic recirculation in most
patients [10]. The slow hepatic metabolism of 5–50 % of
the drug has been shown to occur over 3 days in in vitro
studies [11]. Among the 44 patients who received either
rosuvastatin or atorvastatin, there was no statistically sig-
nificant difference between both drugs in lowering the
LDL-C and TC/HDL-C ratio.
Although rosuvastatin will soon be generic, and ator-
vastatin has been available in a generic form for several
years, when the study was initiated, the cost of rosuvastatin
or atorvastatin was over $US5 per tablet. During the course
of this study, our group of patients saved approximately
$US42,195 with periodic treatment compared with con-
ventional daily dosing. Using our data, the cost savings for
treating 1 million patients, at the current cash cost of 90
generic atorvastatin for $US53 [12] would be a savings of
$US197 million per year. Supported by the pharmacoki-
netics of these two drugs, a dosing schedule of every other
day may permit effective treatment with a 50 % savings to
the patient. Periodic rosuvastatin and atorvastatin dosing
from once weekly to every other day has been studied and
been shown to result in significant cholesterol reduction.
Our study is the first to adapt a pragmatic stepwise
approach, offering patient input to manage their hyperlip-
idemia. During the 8-year period, the patients were given
the opportunity to choose a dosage regimen based on how
they responded to treatment with a defined goal of TC/
HDL-C ratio \5. Using a patient-directed stepwise
approach, we demonstrated sustained patient adherence of
95.7 %, which compares favorably with figures for daily
dosing from the literature. Several studies have found
36–60 % of the patients were adherent to prescribed statin
dosing after 12 months [13, 14]. Patient-directed therapy
promoted an acceptable quality of life while reaching the
stated lipid treatment goals in an office setting. This study
adds evidence to the utility of a patient-centered approach
to managing hyperlipidemia in select patients. Limitations
of the study include the small cohort and the retrospective
design nature. There was no cardiovascular endpoint
measurement to see whether this treatment strategy was
associated with favorable cardiovascular outcomes
compared with daily statin dosing. Although no cardiac
events occurred during the 8 years reviewed, additional
comparative studies with a larger patient population are
required to confirm the long-term cardioprotective effects
of periodic statin dosing.
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